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Phosphoinositide 3-Kinase (PI3K) is a central enzyme in
a signaling pathway that mediates cellular responses to
growth factors. This enzyme phosphorylates the 3 posi-
tion of phosphatidylinositol-4,5-bisphosphate to produce
phosphatidylinositol-3,4,5-trisphosphate (PIP3)a tt h e
plasma membrane. A number of signaling proteins,
including the Ser/Thr protein kinases, AKT and PDK1,
contain pleckstrin homology domains that bind specifi-
cally to PIP3. Thus, the generation of PIP3 at the plasma
membrane in response to activation of PI3K by growth
factors results in the initiation of downstream Ser/Thr
phosphorylation cascades that control a variety of cellular
responses. The signaling pathway downstream of PI3K is
highly conserved from worms and flies to humans and
genetic analysis of the pathway has revealed a conserved
role in regulating glucose metabolism and cell growth.
Based on deletion of genes encoding the catalytic or regu-
latory subunits of PI3K in the mouse, PI3K mediates insu-
lin dependent regulation of glucose metabolism, and
defects in activation of this pathway result in insulin resis-
tance. In contrast, mutational events that lead to hyperac-
tivation of the PI3K pathway result in cancers. Activating
mutations in PIK3CA, encoding the p110alpha catalytic
subunit of PI3K or inactivating mutations in PTEN, a phos-
phoinositide 3-phosphatases that reverses the effects of
PI3K, are among the most common events in solid tumors.
We have generated mouse models in which a mutated
form of the PIK3CA gene is expressed in a tissue specific
and reversibly inducible manner. These mice develop can-
cers that are dependent on continuous expression of the
mutant PIK3CA gene. The PIK3CA driven tumors are
FDG-PET positive and turning off PI 3-Kinase with PI3K
inhibitors that are in human clinical trials results in an
acute decline in FDG-PET signal that precedes tumor
shrinkage. These results suggest that the ability of PI3K to
stimulate high rates of glucose uptake and metabolism may
be critical for the survival of PIK3CA mutant tumors. The
role of PI3K inhibitors for treating cancers in mouse mod-
els and in human trials will be discussed.
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